R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds

Pharma R&D: Divergent Paths of MannKind and Pharming

__timestampMannKind CorporationPharming Group N.V.
Wednesday, January 1, 201410024400014182353
Thursday, January 1, 20152967400015503028
Friday, January 1, 20161491700016183585
Sunday, January 1, 20171411800022382849
Monday, January 1, 2018873700033038206
Tuesday, January 1, 2019690000031777040
Wednesday, January 1, 2020624800041464134
Friday, January 1, 20211231200067178053
Saturday, January 1, 20221972100052531000
Sunday, January 1, 20233128300068914000
Loading chart...

Unlocking the unknown

R&D Spending Trends in the Pharmaceutical Sector

In the ever-evolving pharmaceutical industry, research and development (R&D) is the lifeblood of innovation. Over the past decade, MannKind Corporation and Pharming Group N.V. have demonstrated contrasting strategies in their R&D investments. MannKind's R&D expenses peaked in 2014, with a significant 41% of their total expenditure over the decade, before experiencing a sharp decline. By 2020, their spending had decreased by nearly 94%, reflecting a strategic shift or financial constraints.

Conversely, Pharming Group N.V. has shown a steady increase in R&D allocation, with a notable 386% rise from 2014 to 2023. This upward trend underscores their commitment to innovation and growth. By 2023, Pharming's R&D spending was nearly double that of MannKind, highlighting their aggressive pursuit of new therapeutic solutions. These trends offer a glimpse into the strategic priorities of these companies and their potential impact on future pharmaceutical advancements.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025